SCHEMBL16626455

SCHEMBL16626455

CNCc1cn(S(=O)(=O)c2cccc(F)c2)c2cc(Nc3ccc(C)cc3Cl)ccc12

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.42
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
FBP1 P09467 1/20 0.36
IDE P14735 1/20 0.36
NPC1 O15118 1/20 0.35
ALK Q9UM73 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619415 0.99 HTR6 (0.41) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626508 0.91 HTR6 (0.43) HTR6IDENPC1ALKL3MBTL1
SCHEMBL17971554 0.91 HTR6 (0.43) HTR6IDENPC1ALKL3MBTL1
SCHEMBL16626496 0.91 HTR6 (0.45) HTR6PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16619225 0.90 HTR6 (0.42) HTR6IDENPC1ALKDRD2
Hydrochloric Acid SCHEMBL16619339 0.90 HTR6 (0.44) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626745 0.90 RORC (0.39) HTR6PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16619472 0.89 RORC (0.38) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL17971555 0.89 HTR6 (0.44) HTR6
SCHEMBL16626518 0.88 HTR6 (0.43) HTR6FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885PDE4A 2460/4885PDE4B 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.